Page last updated: 2024-08-26

fulvestrant and Alopecia

fulvestrant has been researched along with Alopecia in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Buisseret, L; de Azambuja, E; Eiger, D; Nogueira, MS; Pondé, NF; Wagner, M	1
Handjiski, B; Ohnemus, U; Paus, R; Unalan, M	1
Frank, LA	1
Gassmueller, J; Hoffmann, R; Webster, A	1

Reviews

1 review(s) available for fulvestrant and Alopecia

Article	Year
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). Acta oncologica (Stockholm, Sweden), 2020, Volume: 59, Issue:6 Topics: Alopecia; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Fulvestrant; Germany; Humans; Incidence; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Survival Rate; Tamoxifen	2020

Article

Year

The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).

Acta oncologica (Stockholm, Sweden), 2020, Volume: 59, Issue:6

Topics: Alopecia; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Fulvestrant; Germany; Humans; Incidence; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Survival Rate; Tamoxifen

2020

Trials

2 trial(s) available for fulvestrant and Alopecia

Article	Year
Oestrogen receptor antagonist and hair regrowth in dogs with hair cycle arrest (alopecia X). Veterinary dermatology, 2007, Volume: 18, Issue:1 Topics: Alopecia; Animals; Dog Diseases; Dogs; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hair Follicle; Injections, Intramuscular; Male; Severity of Illness Index; Treatment Outcome	2007
Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. The British journal of dermatology, 2008, Volume: 158, Issue:1 Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hair; Humans; Male; Middle Aged; Minoxidil; Severity of Illness Index; Treatment Outcome; Vasodilator Agents	2008

Article

Year

Oestrogen receptor antagonist and hair regrowth in dogs with hair cycle arrest (alopecia X).

Veterinary dermatology, 2007, Volume: 18, Issue:1

Topics: Alopecia; Animals; Dog Diseases; Dogs; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hair Follicle; Injections, Intramuscular; Male; Severity of Illness Index; Treatment Outcome

2007

Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies.

The British journal of dermatology, 2008, Volume: 158, Issue:1

Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hair; Humans; Male; Middle Aged; Minoxidil; Severity of Illness Index; Treatment Outcome; Vasodilator Agents

2008

Other Studies

1 other study(ies) available for fulvestrant and Alopecia

Article	Year
Topical estrogen accelerates hair regrowth in mice after chemotherapy-induced alopecia by favoring the dystrophic catagen response pathway to damage. The Journal of investigative dermatology, 2004, Volume: 122, Issue:1 Topics: Administration, Topical; Alopecia; Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hair; Mice; Mice, Inbred C57BL	2004

Article

Year

Topical estrogen accelerates hair regrowth in mice after chemotherapy-induced alopecia by favoring the dystrophic catagen response pathway to damage.

The Journal of investigative dermatology, 2004, Volume: 122, Issue:1

Topics: Administration, Topical; Alopecia; Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hair; Mice; Mice, Inbred C57BL

2004